Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Exosens's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 29.398.
Exosens's Days Inventory for the
six
months ended in Dec. 2025 was 56.838.
Exosens's Days Payable for the
six
months ended in Dec. 2025 was 16.721.
Therefore, Exosens's Cash Conversion Cycle (CCC) for the
six
months ended in Dec. 2025 was 69.52.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Exosens Cash Conversion Cycle Related Terms
Exosens Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Exosens's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:0EXO vs VRT, BE: Cash Conversion Cycle Comparison
For the Aerospace & Defense subindustry, Exosens's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Exosens Cash Conversion Cycle vs Aerospace & Defense Industry
For the Aerospace & Defense industry and Industrials sector, Exosens's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Exosens's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Exosens's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Exosens (LSE:0EXO) has a Cash Conversion Cycle of 69.52 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Exosens and its competitors.
Is Exosens' Cash Conversion Cycle too high?
Exosens' current Cash Conversion Cycle is 69.52. The Aerospace & Defense industry median Cash Conversion Cycle is 127.95. Exosens' value of 69.52 is 45.7% below this industry median. Overall, Exosens has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Exosens' Cash Conversion Cycle compare to VRT and BE?
Exosens' Cash Conversion Cycle of 69.52 can be compared against companies in the Aerospace & Defense industry. The industry median Cash Conversion Cycle is 127.95. Exosens' value of 69.52 is 45.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for an Aerospace & Defense company?
The median Cash Conversion Cycle among Aerospace & Defense companies is 127.95, based on 356 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Exosens's current Cash Conversion Cycle of 69.52 is 45.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Exosens and its competitors. For the Aerospace & Defense industry, the median Cash Conversion Cycle is 127.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Exosens's current Cash Conversion Cycle is 69.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exosens stock overvalued right now?
Exosens (LSE:0EXO) has a current Cash Conversion Cycle of 69.52. The current Cash Conversion Cycle is 69.52 and 45.7% below the Aerospace & Defense industry median of 127.95. Exosens' overall GF Score™ is 39/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Exosens (LSE:0EXO), the current Cash Conversion Cycle is 69.52 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Exosens SA is a high-tech company specializing in electro-optical technologies for amplification, detection, and imaging. It offers products such as night vision tubes, ultraviolet cameras, travelling wave tubes, and various detectors for defense, life sciences, nuclear, and industrial sectors. With multiple production sites in Europe and North America. The company's activities are organized into two main segments: Amplification, which focuses on electron or electromagnetic wave amplification systems mainly used in defense night vision equipment and generates the majority of its revenue, and Detection & Imaging, which provides high value-added components for commercial markets such as nuclear power, research, and industrial applications.
39GF Score
Get the complete analysis for LSE:0EXO
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:0EXO has been successfully added to your 
